Dynavax Technologies announced its plans to lay off more than 1/3 of its staff. The company is
The company plans to ax 37% of its staff as it shifts its business away from immuno-oncology and prioritizes its vaccine workstream.
Focus of Dynavax will be support for Heplisav-B, this should be its first commercial product.
The shift of its focus will cause Dynavax Technologies to cut 82 positions, primarily those related to research and clinical development for the immuno-oncology programs, as well as general and admin functions.
CEO Eddie Gray will step down as well...